Literature DB >> 28025615

ErbB3 emerges as an exciting therapeutic target in osteosarcoma.

.   

Abstract

Entities:  

Year:  2013        PMID： 28025615      PMCID： PMC5154237          DOI： 10.1038/bonekey.2013.142

Source DB:  PubMed          Journal:  Bonekey Rep        ISSN： 2047-6396


× No keyword cloud information.
  1 in total

1.  ErbB3 silencing reduces osteosarcoma cell proliferation and tumor growth in vivo.

Authors:  Nicolas Jullien; François-Xavier Dieudonné; Nadia Habel; Caroline Marty; Dominique Modrowski; Ana Patino; Fernando Lecanda; Nicolas Sévère; Pierre J Marie
Journal:  Gene       Date:  2013-03-27       Impact factor: 3.688
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.